LXA4 protects against hypoxic-ischemic damage in neonatal rats by reducing the inflammatory response via the IκB/NF-κB pathway
Copyright © 2020. Published by Elsevier B.V..
Hypoxia and the resultant decreases in cerebral blood flow in the perinatal period can lead to neonatal hypoxic-ischemic (HI) brain injury, which can, in turn, cause severe disability or even death. However, the efficacy of current treatment strategies remains limited. Several studies have demonstrated that lipoxin A4 (LXA4), as one of the earliest types of endogenous lipid mediators, can inhibit the accumulation of neutrophils, arrest inflammation, and promote the resolution of inflammation. However, research on LXA4 in the nervous system has rarely been carried out. In the present study, we sought to investigate the protective effect of LXA4 on HI brain damage in neonatal rats, as well as the underlying mechanisms. Through experiments conducted using an HI animal model, we found that the LXA4 intervention promoted the recovery of neuronal function and tissue structure following brain injury while maintaining the integrity of the blood-brain barrier in addition to reducing cerebral edema, infarct volume, and inflammatory responses. Our results suggest that LXA4 interfered with neuronal oxygen-glucose deprivation insults, reduced the expression of inflammatory factors, inhibited apoptosis, and promoted neuronal survival in vitro. Finally, the LXA4 intervention attenuated HI-induced activation of inhibitor kappa B (IκB) and degradation of nuclear factor-κB (NF-κB). In conclusion, our data suggest that LXA4 exerts a neuroprotective effect against neonatal HI brain damage through the IκB/NF-κB pathway. Our findings will help inform future studies regarding the effects of LXA4 on neuroinflammation, blood-brain barrier integrity, and neuronal apoptosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
International immunopharmacology - 89(2020), Pt B vom: 15. Dez., Seite 107095 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Jin-Jin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood–brain barrier |
|---|
| Anmerkungen: |
Date Completed 20.04.2021 Date Revised 20.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2020.107095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316652288 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316652288 | ||
| 003 | DE-627 | ||
| 005 | 20231225161542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2020.107095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316652288 | ||
| 035 | |a (NLM)33096360 | ||
| 035 | |a (PII)S1567-5769(20)32166-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Jin-Jin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LXA4 protects against hypoxic-ischemic damage in neonatal rats by reducing the inflammatory response via the IκB/NF-κB pathway |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2021 | ||
| 500 | |a Date Revised 20.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
| 520 | |a Hypoxia and the resultant decreases in cerebral blood flow in the perinatal period can lead to neonatal hypoxic-ischemic (HI) brain injury, which can, in turn, cause severe disability or even death. However, the efficacy of current treatment strategies remains limited. Several studies have demonstrated that lipoxin A4 (LXA4), as one of the earliest types of endogenous lipid mediators, can inhibit the accumulation of neutrophils, arrest inflammation, and promote the resolution of inflammation. However, research on LXA4 in the nervous system has rarely been carried out. In the present study, we sought to investigate the protective effect of LXA4 on HI brain damage in neonatal rats, as well as the underlying mechanisms. Through experiments conducted using an HI animal model, we found that the LXA4 intervention promoted the recovery of neuronal function and tissue structure following brain injury while maintaining the integrity of the blood-brain barrier in addition to reducing cerebral edema, infarct volume, and inflammatory responses. Our results suggest that LXA4 interfered with neuronal oxygen-glucose deprivation insults, reduced the expression of inflammatory factors, inhibited apoptosis, and promoted neuronal survival in vitro. Finally, the LXA4 intervention attenuated HI-induced activation of inhibitor kappa B (IκB) and degradation of nuclear factor-κB (NF-κB). In conclusion, our data suggest that LXA4 exerts a neuroprotective effect against neonatal HI brain damage through the IκB/NF-κB pathway. Our findings will help inform future studies regarding the effects of LXA4 on neuroinflammation, blood-brain barrier integrity, and neuronal apoptosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Blood–brain barrier | |
| 650 | 4 | |a Hypoxic-ischemic | |
| 650 | 4 | |a IκB/NF-κB | |
| 650 | 4 | |a Neuroinflammation | |
| 650 | 7 | |a I-kappa B Proteins |2 NLM | |
| 650 | 7 | |a Lipoxins |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 650 | 7 | |a lipoxin A4 |2 NLM | |
| 700 | 1 | |a Yu, Bin-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Chang-Chang |e verfasserin |4 aut | |
| 700 | 1 | |a He, Min-Zhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jiang-Hu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Bin-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yi-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shang-Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Xiao-Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Pei-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Zhen-Lang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 89(2020), Pt B vom: 15. Dez., Seite 107095 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2020 |g number:Pt B |g day:15 |g month:12 |g pages:107095 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2020.107095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2020 |e Pt B |b 15 |c 12 |h 107095 | ||